Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.19 EPS, down 36.84% or $0.07 from last year’s $-0.12 per share.

At the moment 5 analysts are watching Inovio Pharmaceuticals, Inc. (NASDAQ:INO), 2 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 2 analysts have a mean sales target of 3.97 million. For the quarter ending Jun-16, 2 analysts have a mean sales target of 3.97 million whilst for the year ending Dec-16, 5 analysts have a mean target of 37.31 million.

In terms of earnings per share, 3 analysts have a -0.12 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a -0.07 EPS mean target and for the quarter ending Jun-16 there are 5 estimates of -0.71 EPS.

The biggest institutional shareholders in Inovio Pharmaceuticals, Inc. include BlackRock Advisors LLC which owns 5 million shares in the company valued at $33.20 million. State Street Corp is the second biggest holder with 4 million shares currently valued at 25.84 million whilst BlackRock Fund Advisors has 3 million shares valued at 16.83 million.

Total shares held by institutions as of the most recent company filings are 27,587,318 with a reported 2,394,011 bought and 1,350,693 sold. These holdings make up 38.45% of the company’s outstanding shares.

Currently insiders hold 4,460,271 shares in the business which makes up 6.18% of shares. The biggest holder currently is Kim Jong Joseph who owns 1,798,078 shares (2.49% of those outstanding), whilst Tee Khiang Ng holds 1,113,923 (1.54% of shares outstanding) and Kevin Rassas holds 726,088 (1.01% of shares outstanding).

The stock increased 2.69% or $0.18 during the last trading session, hitting $7.94. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has risen 7.43% over the past 6 months and is uptrending.